ERNA vs. CELZ, EDSA, BLRX, ORGS, PRPH, ALZN, OMGA, CMND, CNSP, and GLTO
Should you be buying Eterna Therapeutics stock or one of its competitors? The main competitors of Eterna Therapeutics include Creative Medical Technology (CELZ), Edesa Biotech (EDSA), BioLineRx (BLRX), Orgenesis (ORGS), ProPhase Labs (PRPH), Alzamend Neuro (ALZN), Omega Therapeutics (OMGA), Clearmind Medicine (CMND), CNS Pharmaceuticals (CNSP), and Galecto (GLTO). These companies are all part of the "pharmaceutical products" industry.
Eterna Therapeutics vs.
Creative Medical Technology (NASDAQ:CELZ) and Eterna Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.
Creative Medical Technology has a net margin of 0.00% compared to Eterna Therapeutics' net margin of -7,513.88%. Eterna Therapeutics' return on equity of 0.00% beat Creative Medical Technology's return on equity.
In the previous week, Creative Medical Technology had 3 more articles in the media than Eterna Therapeutics. MarketBeat recorded 3 mentions for Creative Medical Technology and 0 mentions for Eterna Therapeutics. Eterna Therapeutics' average media sentiment score of 0.00 beat Creative Medical Technology's score of -0.75 indicating that Eterna Therapeutics is being referred to more favorably in the news media.
Creative Medical Technology has higher earnings, but lower revenue than Eterna Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks.
1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are held by institutional investors. 2.8% of Creative Medical Technology shares are held by company insiders. Comparatively, 4.5% of Eterna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Creative Medical Technology received 71 more outperform votes than Eterna Therapeutics when rated by MarketBeat users.
Creative Medical Technology has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 4.29, indicating that its share price is 329% more volatile than the S&P 500.
Summary
Creative Medical Technology beats Eterna Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Eterna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eterna Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ERNA) was last updated on 2/22/2025 by MarketBeat.com Staff
